Why the study?
Does sirolimus-eluting stent implantation reduce major adverse cardiac events compared to paclitaxel-eluting stents in patients with complex coronary features?
Does sirolimus-eluting stent implantation reduce major adverse cardiac events compared to paclitaxel-eluting stents in patients with complex coronary features?
In patients with complex coronary lesions, sirolimus-eluting and paclitaxel-eluting stents demonstrate comparable rates of major adverse cardiac events at 12 months.
No takes yet. Share an insight, caveat, or question.
May support SES preference over PES in complex lesions; leaves open need for randomized confirmation.
Roy et al. (2007) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: